- Home
- DNTH vs CRMD Comparison
DNTH vs CRMD Comparison
Compare DNTH & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DNTH
- CRMD
- Stock Information
- Founded
- DNTH 2015
- CRMD 2006
- Country
- DNTH United States
- CRMD United States
- Employees
- DNTH N/A
- CRMD N/A
- Industry
- DNTH Biotechnology: Pharmaceutical Preparations
- CRMD Biotechnology: Pharmaceutical Preparations
- Sector
- DNTH Health Care
- CRMD Health Care
- Exchange
- DNTH Nasdaq
- CRMD Nasdaq
- Market Cap
- DNTH 711.2M
- CRMD 576.4M
- IPO Year
- DNTH N/A
- CRMD 2010
- Fundamental
- Price
- DNTH $23.80
- CRMD $8.57
- Analyst Decision
- DNTH Strong Buy
- CRMD Strong Buy
- Analyst Count
- DNTH 9
- CRMD 5
- Target Price
- DNTH $46.43
- CRMD $15.80
- AVG Volume (30 Days)
- DNTH 203.7K
- CRMD 945.5K
- Earning Date
- DNTH 11-07-2024
- CRMD 10-30-2024
- Dividend Yield
- DNTH N/A
- CRMD N/A
- EPS Growth
- DNTH N/A
- CRMD N/A
- EPS
- DNTH N/A
- CRMD N/A
- Revenue
- DNTH $5,366,000.00
- CRMD $12,262,234.00
- Revenue This Year
- DNTH $98.73
- CRMD N/A
- Revenue Next Year
- DNTH N/A
- CRMD $277.75
- P/E Ratio
- DNTH N/A
- CRMD N/A
- Revenue Growth
- DNTH 51.41
- CRMD 41184.20
- 52 Week Low
- DNTH $8.24
- CRMD $2.89
- 52 Week High
- DNTH $33.77
- CRMD $13.85
- Technical
- Relative Strength Index (RSI)
- DNTH 46.14
- CRMD 40.01
- Support Level
- DNTH $22.59
- CRMD $8.00
- Resistance Level
- DNTH $24.57
- CRMD $9.02
- Average True Range (ATR)
- DNTH 1.49
- CRMD 0.51
- MACD
- DNTH 0.04
- CRMD -0.07
- Stochastic Oscillator
- DNTH 30.84
- CRMD 28.93
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.
About CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets.